Narrow band Ultraviolet B 311 nm in the treatment of vitiligo: two right–left comparison studies

Mofty, Medhat El; Mostafa, Wedad Z.; Esmat, Samia; Youssef, Randa; Abu-Azzam, Omar; Hunter, Nahla; Hanafi, G. El; Fawzi, May

doi:10.1111/j.1600-0781.2006.00189.x

Cited by 51 publications

(44 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neste estudo, não foram utilizados medicamentos e pomadas associadas ao tratamento, porém, estudos anteriores, realizados com UVB associado a pomada e/ou medicamentos e somente com o UVB demonstraram que o tratamento associado a outro método é mais e icaz, concluindo, portanto, que eles podem ser um método coadjuvante para o tratamento do vitiligo (17,23,26,27). Middelkamp-Hup et al (26) constataram que a repigmentação foi considerada clinicamente relevante em 72% dos casos de um grupo que fez combinação do UVB com leucotomos P. (cápsula antioxidante), em relação ao grupo que utilizou placebo e UVB.…”

Section: Discussionunclassified

“…O UVB tem ação direta sobre os queratinócitos, induzindo alterações estruturais e funcionais por meio de fenômenos imunológicos e maior produção de citocinas imunossupressoras que estimulam a migração e proliferação dos melanócitos (15,16). Indicações para a fototerapia com UVB são mais adequadas para psoríase, pitiríase rósea, foliculite pustulosa, pitiríase liquenóide crônica, controle do prurido e vitiligo (15,17,18).…”

Section: D]unclassified

See 1 more Smart Citation

Efeitos da aplicação do L.A.S.E.R. HeNe e do ultravioleta B no vitiligo

Macedo

Oliveira²,

Silva³

et al. 2012

Fisioter. mov.

View full text Add to dashboard Cite

Fisioter Mov. 2012 jul/set;25(3):481-8 ISSN 0103-5150 Fisioter. Mov., Curitiba, v. 25, n. 3, p. 481-488, jul./set. 2012 Licenciado sob uma Licença Creative Commons [T] Efeitos da aplicação do L.A.S.E.R. HeNe e do ultravioleta B no vitiligo foi de 4,43 cm² ± 5,17, com diferença média de 0,92 cm² ± 1,29. Conclusão: Ambos os aparelhos obtiveram resultados signi icativos na redução da mácula, com maior redução no grupo da ultravioleta. Application purposes of HeNe L.A.S.E.R. and ultraviolet B in vitiligo[P] [K] Palavras

show abstract

Section: Discussionunclassified

Section: D]unclassified

Efeitos da aplicação do L.A.S.E.R. HeNe e do ultravioleta B no vitiligo

Macedo

Oliveira²,

Silva³

et al. 2012

Fisioter. mov.

View full text Add to dashboard Cite

show abstract

“…This analysis also revealed that PUVA is associated with the highest rates of side effects. On the other hand, El Mofty and colleagues showed that NB-UVB photo therapy had a similar repigmentary effect as PUVA (El Mofty et al, 2006). By comparing these findings, NB-UVB is choice treatment for extensive vitiligo.…”

Section: Phototherapymentioning

confidence: 94%

Role of Corticosteroids in Treatment of Vitiligo

Bagherani¹

2012

State of the Art of Therapeutic Endocrinology

View full text Add to dashboard Cite

“…367 A total of seven studies were excluded. [390][391][392][393][394][395][396] The reasons are documented in the full version of the review (see 'Characteristics of excluded studies ' table 367 ). In addition, 13 studies were omitted on the basis that they were awaiting classification and five were ongoing at the time of the review.…”

Section: Randomised Controlled Trials Included In This Reviewmentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Narrow band Ultraviolet B 311 nm in the treatment of vitiligo: two right–left comparison studies

Abstract: NB UVB 311 nm has similar repigmentary effects as PUVA. The addition of psoralen does not increase its efficacy.

Cited by 51 publications

References 18 publications

Efeitos da aplicação do L.A.S.E.R. HeNe e do ultravioleta B no vitiligo

Efeitos da aplicação do L.A.S.E.R. HeNe e do ultravioleta B no vitiligo

Role of Corticosteroids in Treatment of Vitiligo

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Contact Info

Product

Resources

About